REACTIVE OXYGEN SPECIES INDUCED NEURODEGENERATION IN ALZHEIMER'S DISEASE

被引:0
作者
Obreshkova, D. [1 ]
机构
[1] Med Univ Sofia, Fac Pharm, Dept Pharmaceut Chem, Sofia, Bulgaria
关键词
oxidative stress; neurodegeneration; Alzheimer's disease; antioxidants;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxidative stress is caused by an imbalance between the prooxidant and antioxidant systems. In neuropathology of Alzheimer's disease the important markers of oxidative stress in brain are senile plaques, neurofibrillary tangles, protein and nucleic acid oxidation, lipid peroxidation and mitochondrial abnormalities. Amyloid - beta aggregates deposition in brain induces oxidative changes and generation of an oxidative microenvironment. The increased levels of soluble amyloid - beta(1-42) oligomers lead to neurodegeneration, memory deficits and loss of connectivity by causing aberrations in synapse composition, synapse and dendritic loss and abnormalities. Amyloid - beta proteins and mitochondrial oxidative stress cause hyperphosphorylation of tau protein. Soluble hyperphosphorylated tau oligomers disrupt synaptic function and are involved in synapse loss. For pharmacological treatment of Alzheimer's disease the most important drug discovery strategies include application of antioxidants and inhibitors of acethylcholinesterase, gamma - secretase and aggregation of tau protein.
引用
收藏
页码:71 / 82
页数:12
相关论文
共 144 条
  • [81] Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease
    Marcus, Jacob Newman
    Schachter, Joel
    [J]. JOURNAL OF NEUROGENETICS, 2011, 25 (04) : 127 - 133
  • [82] Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment
    Markesbery, William R.
    Lovell, Mark A.
    [J]. ARCHIVES OF NEUROLOGY, 2007, 64 (07) : 954 - 956
  • [83] Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference
    Marra, G
    Cotroneo, P
    Pitocco, D
    Manto, A
    Di Leo, MAS
    Ruotolo, V
    Caputo, S
    Giardina, B
    Ghirlanda, G
    Santini, SA
    [J]. DIABETES CARE, 2002, 25 (02) : 370 - 375
  • [84] Massaad CA, 2011, CURR NEUROPHARMACOL, V9, P662, DOI 10.2174/157015911798376244
  • [85] Pharmacological Treatment of Alzheimer Disease
    Massoud, Fadi
    Leger, Gabriel C.
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2011, 56 (10): : 579 - 588
  • [86] Amyloid β-peptide induces apoptosis-related events in synapses and dendrites
    Mattson, MP
    Partin, J
    Begley, JG
    [J]. BRAIN RESEARCH, 1998, 807 (1-2) : 167 - 176
  • [87] Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau
    Melov, Simon
    Adlard, Paul A.
    Morten, Karl
    Johnson, Felicity
    Golden, Tamara R.
    Hinerfeld, Doug
    Schilling, Birgit
    Mavros, Christine
    Masters, Colin L.
    Volitakis, Irene
    Li, Qiao-Xin
    Laughton, Katrina
    Hubbard, Alan
    Cherny, Robert A.
    Gibson, Brad
    Bush, Ashley I.
    [J]. PLOS ONE, 2007, 2 (06):
  • [88] Role of the region 23-28 in Aβ fibril formation:: Insights from simulations of the monomers and dimers of Alzheimer's peptides Aβ40 and Aβ42
    Melquiond, Adrien
    Dong, Xiao
    Mousseau, Normand
    Derreumaux, Philippe
    [J]. CURRENT ALZHEIMER RESEARCH, 2008, 5 (03) : 244 - 250
  • [89] Protein denaturation and aggregation - Cellular responses to denatured and aggregated proteins
    Meredith, Stephen C.
    [J]. CELL INJURY: MECHANISMS, RESPONSES, AND REPAIR, 2005, 1066 : 181 - 221
  • [90] Relationship Between Tau Pathology and Neuroinflammation in Alzheimer's Disease
    Metcalfe, Maria Jose
    Figueiredo-Pereira, Maria E.
    [J]. MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (01): : 50 - 58